semaglutide chronic kidney disease and Survival Benefits of in Diabetes With Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses semaglutide and chronic kidney disease

Wegovy contains the active ingredient semaglutide, a GLP-1 agonist

Semaglutide users have reported an average weight loss of 15% of initial body weight, while Tirzepatide users have seen losses of 21% to 25%

Analysis of GLP-1 Diabetes Treatment Drugs Market in China GLP-1 diabetes treatment drugs in China is projected to exhibit exceptional growth with a CAGR of 34.2% through 2035, driven by the rapidly expanding diabetes population and massive government investments in healthcare infrastructure development across major urban centers

Consulting with a Healthcare Professional Patients considering or currently using GLP-1 agonists should seek personalised guidance from healthcare professionals

Given that clinical trials often exclude those with mood disorders, heightened awareness and monitoring are crucial when prescribing GLP-1s to individuals with bipolar disorder, it is necessary to educate both medical professionals and patients regarding potential effects